O	0	6	Weekly
B-intervention	7	16	docetaxel
O	17	23	versus
B-control	24	27	CMF
O	28	30	as
O	31	39	adjuvant
O	40	52	chemotherapy
O	53	56	for
O	57	64	elderly
O	65	71	breast
O	72	78	cancer
O	79	87	patients
O	87	88	:
O	89	95	safety
O	96	100	data
O	101	105	from
O	106	109	the
O	110	121	multicentre
O	122	127	phase
O	128	129	3
O	130	140	randomised
O	141	145	ELDA
O	146	151	trial
O	151	152	.

O	153	159	Within
O	160	162	an
O	163	170	ongoing
O	171	182	multicentre
O	183	188	phase
O	189	190	3
O	191	201	randomised
O	202	207	trial
O	208	209	(
O	209	213	ELDA
O	213	214	,
O	215	227	cancertrials
O	227	228	.
O	229	232	gov
O	233	235	ID
O	235	236	:
O	237	248	NCT00331097
O	248	249	)
O	249	250	,
B-eligibility	251	256	early
I-eligibility	257	263	breast
I-eligibility	264	270	cancer
I-eligibility	271	279	patients
I-eligibility	279	280	,
I-eligibility	281	283	65
I-eligibility	283	284	-
I-eligibility	284	286	79
I-eligibility	287	292	years
I-eligibility	293	296	old
I-eligibility	296	297	,
I-eligibility	298	302	with
I-eligibility	303	310	average
I-eligibility	311	313	to
I-eligibility	314	318	high
I-eligibility	319	323	risk
I-eligibility	324	326	of
I-eligibility	327	337	recurrence
O	337	338	,
O	339	342	are
O	343	351	randomly
O	352	360	assigned
O	361	363	to
O	364	371	receive
O	372	375	CMF
O	376	377	(
O	377	393	cyclophosphamide
O	394	397	600
O	398	400	mg
O	400	401	/
O	401	403	m2
O	403	404	,
O	405	417	methotrexate
O	418	420	40
O	421	423	mg
O	423	424	/
O	424	426	m2
O	426	427	,
O	428	440	fluorouracil
O	441	444	600
O	445	447	mg
O	447	448	/
O	448	450	m2
O	450	451	,
O	452	456	days
O	457	458	1
O	458	459	-
O	459	460	8
O	460	461	)
O	462	464	or
O	465	474	docetaxel
O	475	476	(
O	476	478	35
O	479	481	mg
O	481	482	/
O	482	484	m2
O	485	489	days
O	490	491	1
O	491	492	-
O	492	493	8
O	493	494	-
O	494	496	15
O	496	497	)
O	497	498	,
O	499	504	every
O	505	506	4
O	507	512	weeks
O	512	513	.

O	514	518	Here
O	519	521	we
O	522	528	report
O	529	531	an
O	532	541	unplanned
O	542	548	safety
O	549	557	analysis
O	558	566	prompted
O	567	569	by
O	570	572	an
O	573	582	amendment
O	583	594	introducing
O	595	605	creatinine
O	606	615	clearance
O	616	618	as
O	619	620	a
O	621	625	tool
O	626	628	to
O	629	635	adjust
O	636	648	methotrexate
O	649	653	dose
O	653	654	.

O	655	661	Before
O	662	666	such
O	667	673	change
O	673	674	,
B-total-participants	675	678	101
O	679	687	patients
O	688	692	with
O	693	694	a
O	695	701	median
O	702	705	age
O	706	708	of
B-age	709	711	70
O	712	716	were
O	717	725	randomly
O	726	734	assigned
O	735	738	CMF
O	739	740	(
B-control-participants	740	742	53
O	743	751	patients
O	751	752	)
O	753	755	or
O	756	765	docetaxel
O	766	767	(
B-intervention-participants	767	769	48
O	770	778	patients
O	778	779	)
O	779	780	.

O	781	783	At
O	784	789	least
O	790	793	one
B-outcome	794	800	grades
I-outcome	801	802	3
I-outcome	802	803	-
I-outcome	803	804	4
I-outcome	805	810	toxic
I-outcome	811	816	event
I-outcome	817	819	of
I-outcome	820	823	any
I-outcome	824	828	type
O	829	832	was
O	833	841	reported
O	842	844	in
B-cv-bin-abs	845	847	40
O	848	849	(
B-cv-bin-percent	849	851	75
I-cv-bin-percent	851	852	.
I-cv-bin-percent	852	853	5
I-cv-bin-percent	853	854	%
O	854	855	)
O	856	859	and
B-iv-bin-abs	860	862	19
O	863	864	(
B-iv-bin-percent	864	866	39
I-iv-bin-percent	866	867	.
I-iv-bin-percent	867	868	6
I-iv-bin-percent	868	869	%
O	869	870	)
O	871	879	patients
O	880	884	with
O	885	888	CMF
O	889	892	and
O	893	902	docetaxel
O	902	903	,
O	904	916	respectively
O	917	918	(
O	918	919	p
O	919	920	=
O	920	921	0
O	921	922	.
O	922	926	0002
O	926	927	)
O	927	928	.

B-outcome	929	935	Grades
I-outcome	936	937	3
I-outcome	937	938	-
I-outcome	938	939	4
I-outcome	940	953	hematological
I-outcome	954	960	events
O	961	965	were
O	966	974	observed
O	975	977	in
B-cv-bin-abs	978	980	37
O	981	982	(
B-cv-bin-percent	982	984	69
I-cv-bin-percent	984	985	.
I-cv-bin-percent	985	986	8
I-cv-bin-percent	986	987	%
O	987	988	)
O	989	991	vs
O	991	992	.
B-iv-bin-abs	993	994	4
O	995	996	(
B-iv-bin-percent	996	997	8
I-iv-bin-percent	997	998	.
I-iv-bin-percent	998	999	3
I-iv-bin-percent	999	1000	%
O	1000	1001	)
O	1002	1007	cases
O	1008	1009	(
O	1009	1010	p
O	1010	1011	<
O	1011	1012	0
O	1012	1013	.
O	1013	1017	0001
O	1017	1018	)
O	1019	1022	and
B-outcome	1023	1029	grades
I-outcome	1030	1031	3
I-outcome	1031	1032	-
I-outcome	1032	1033	4
I-outcome	1034	1037	non
I-outcome	1037	1038	-
I-outcome	1038	1051	hematological
I-outcome	1052	1060	toxicity
O	1061	1063	in
B-cv-bin-abs	1064	1066	12
O	1067	1068	(
B-cv-bin-percent	1068	1070	22
I-cv-bin-percent	1070	1071	.
I-cv-bin-percent	1071	1072	6
I-cv-bin-percent	1072	1073	%
O	1073	1074	)
O	1075	1077	vs
O	1077	1078	.
B-iv-bin-abs	1079	1081	15
O	1082	1083	(
B-iv-bin-percent	1083	1085	31
I-iv-bin-percent	1085	1086	.
I-iv-bin-percent	1086	1087	2
I-iv-bin-percent	1087	1088	%
O	1088	1089	)
O	1090	1098	patients
O	1099	1100	(
O	1100	1101	p
O	1101	1102	=
O	1102	1103	0
O	1103	1104	.
O	1104	1106	11
O	1106	1107	)
O	1107	1108	,
O	1109	1113	with
O	1114	1117	CMF
O	1118	1121	and
O	1122	1131	docetaxel
O	1131	1132	,
O	1133	1145	respectively
O	1145	1146	.

O	1147	1148	A
O	1149	1155	higher
O	1156	1165	incidence
O	1166	1168	of
B-outcome	1169	1175	anemia
O	1175	1176	,
B-outcome	1177	1188	neutropenia
O	1188	1189	,
B-outcome	1190	1206	thrombocytopenia
O	1207	1210	and
B-outcome	1211	1218	febrile
I-outcome	1219	1230	neutropenia
O	1231	1234	was
O	1235	1243	reported
O	1244	1248	with
O	1249	1252	CMF
O	1252	1253	.

B-outcome	1254	1266	Constipation
O	1266	1267	,
B-outcome	1268	1277	mucositis
O	1277	1278	,
B-outcome	1279	1285	nausea
O	1286	1289	and
B-outcome	1290	1298	vomiting
O	1299	1303	were
O	1304	1308	more
O	1309	1315	common
O	1316	1320	with
O	1321	1324	CMF
O	1324	1325	;
B-outcome	1326	1335	diarrhoea
O	1335	1336	,
B-outcome	1337	1346	abdominal
I-outcome	1347	1351	pain
O	1351	1352	,
B-outcome	1353	1362	dysgeusia
O	1362	1363	,
B-outcome	1364	1374	neuropathy
O	1375	1378	and
B-outcome	1379	1384	liver
I-outcome	1385	1393	toxicity
O	1394	1398	were
O	1399	1403	more
O	1404	1412	frequent
O	1413	1417	with
O	1418	1427	docetaxel
O	1427	1428	.

O	1429	1431	No
O	1432	1443	significant
O	1444	1455	interaction
O	1456	1459	was
O	1460	1465	found
O	1466	1473	between
O	1474	1477	the
O	1478	1488	occurrence
O	1489	1491	of
O	1492	1498	severe
B-outcome	1499	1507	toxicity
O	1508	1511	and
O	1512	1520	baseline
O	1521	1530	variables
O	1530	1531	,
O	1532	1541	including
O	1542	1552	creatinine
O	1553	1562	clearance
O	1563	1566	and
O	1567	1576	geriatric
O	1577	1585	activity
O	1586	1592	scales
O	1592	1593	.

O	1594	1596	In
O	1597	1607	conclusion
O	1607	1608	,
O	1609	1615	weekly
O	1616	1625	docetaxel
O	1626	1633	appears
O	1634	1636	to
O	1637	1639	be
O	1640	1644	less
O	1645	1650	toxic
O	1651	1655	than
O	1656	1659	CMF
O	1660	1662	in
O	1663	1668	terms
O	1669	1671	of
O	1672	1685	hematological
O	1686	1694	toxicity
O	1694	1695	.
